TrialBMC cancer2026

Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy.

Xiao-Qian Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.